These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 18513794)

  • 1. Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure.
    Focosi D; Kast RE; Metelli MR; Benedetti E; Galimberti S; Papineschi F; Petrini M
    Leuk Res; 2009 Jan; 33(1):178-81. PubMed ID: 18513794
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin.
    Herman GA; Stein PP; Thornberry NA; Wagner JA
    Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate).
    Kim D; Kowalchick JE; Edmondson SD; Mastracchio A; Xu J; Eiermann GJ; Leiting B; Wu JK; Pryor KD; Patel RA; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3373-7. PubMed ID: 17434732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Biftu T; Feng D; Qian X; Liang GB; Kieczykowski G; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Scapin G; Patel S; Gao YD; Singh S; Wu J; Zhang X; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jan; 17(1):49-52. PubMed ID: 17055272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Sitagliptin. Dipeptidylpeptidase 4 inhibitor for patients with diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2007 Aug; 30(8):282-6; quiz 287-8. PubMed ID: 17879807
    [No Abstract]   [Full Text] [Related]  

  • 6. [Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?].
    Matthes J; Faust M
    Dtsch Med Wochenschr; 2008 Oct; 133(43):2233-7. PubMed ID: 18924057
    [No Abstract]   [Full Text] [Related]  

  • 7. How lithium treatment generates neutrophilia by enhancing phosphorylation of GSK-3, increasing HIF-1 levels and how this path is important during engraftment.
    Kast RE
    Bone Marrow Transplant; 2008 Jan; 41(1):23-6. PubMed ID: 17906701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
    Taldone T; Zito SW; Talele TT
    Bioorg Med Chem Lett; 2008 Jan; 18(2):479-84. PubMed ID: 18068977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DPP-4 inhibitors. A new class of drugs for type 2 diabetes.
    Marino MT
    Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028
    [No Abstract]   [Full Text] [Related]  

  • 11. Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin.
    Biftu T; Scapin G; Singh S; Feng D; Becker JW; Eiermann G; He H; Lyons K; Patel S; Petrov A; Sinha-Roy R; Zhang B; Wu J; Zhang X; Doss GA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3384-7. PubMed ID: 17433672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents.
    Pei Z
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):512-32. PubMed ID: 18600568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of DPP4/CD26 and dmPGE₂ treatment enhances engraftment of mouse bone marrow hematopoietic stem cells.
    Broxmeyer HE; Pelus LM
    Blood Cells Mol Dis; 2014; 53(1-2):34-8. PubMed ID: 24602918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
    Chen P; Caldwell CG; Mathvink RJ; Leiting B; Marsilio F; Patel RA; Wu JK; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5853-7. PubMed ID: 17869513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [DPP-4 inhibition raises incretin levels].
    Warpakowski A
    Med Monatsschr Pharm; 2006 Aug; 29(8):311-2. PubMed ID: 16927605
    [No Abstract]   [Full Text] [Related]  

  • 16. American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors.
    Erlich R
    IDrugs; 2005 Aug; 8(8):611-2. PubMed ID: 16044362
    [No Abstract]   [Full Text] [Related]  

  • 17. Characterization of two cyclic metabolites of sitagliptin.
    Liu DQ; Arison BH; Stearns RA; Kim D; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):521-4. PubMed ID: 17220240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin and simvastatin (juvisync).
    Med Lett Drugs Ther; 2011 Nov; 53(1377):89. PubMed ID: 22075668
    [No Abstract]   [Full Text] [Related]  

  • 19. Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses.
    Reinhold D; Biton A; Goihl A; Pieper S; Lendeckel U; Faust J; Neubert K; Bank U; Täger M; Ansorge S; Brocke S
    Ann N Y Acad Sci; 2007 Sep; 1110():402-9. PubMed ID: 17911455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity of dipeptidyl peptidase IV from C6 rat glioma cells.
    Malík R; Vlasicová L; Kadlecová L; Sedo A
    Neoplasma; 2000; 47(2):96-9. PubMed ID: 10985474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.